Single-agent enfortumab vedotin-ejfv (Padcev) in the neoadjuvant setting had substantial antitumor activity and a high event-free survival (EFS) rate with a manageable toxicity profile in patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC), according to updated data from cohort H of the phase 1b/2 EV-103/KEYNOTE-869 trial (NCT03288545).
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045